Moreover, TOX overexpression exacerbates CD8+ T-cell exhaustion [311], impeding the efficacy of anti-PD-1 therapy in melanoma and NSCLC patients [312,313]. Here, PDCD1 is linked to non-small cell lung carcinoma.